Pangaea Oncology (XMAD:PANG) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:PANG Pangaea Oncology SA XMAD:PANG
65 GF Score
Price €1.55
GF Value €2.19
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Pangaea Oncology FFO per Share?

FFO per Share only applies to REITs.

XMAD:PANG
65GF Score
Pangaea Oncology SA XMAD:PANG
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?

Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued. The current stock price of €1.55 is trading 29.2% below its estimated GF Value™ of €2.19. GuruFocus considers Pangaea Oncology to be Modestly Undervalued.

Key valuation signals for XMAD:PANG:

  • FFO per Share:
  • GF Value™: €2.19 vs. price of €1.55 (29.2% below fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pangaea Oncology Business Description

Address Calle Sabino Arana, 5-19, Barcelona, ESP, 08028
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
65GF Score

Get the complete analysis for XMAD:PANG

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.55
Price
€2.19
GF Value